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Background
Colon cancer initiating cells (CCICs) play important roles
in colorectal cancer (CRC) tumorigenesis. CCICs exhibit
certain stem cell-like features, including self-renewal,
differentiation, and asymmetric division. CCICs are often
identified by their expression of marker CD133 among
other markers. However, it has remained largely unclear
whether CCICs isolated from different CRC tumors share
common mechanisms that account for their phenotype, or
are completely different cells that were categorized simply
by their tumorigenic capacity.
Materials and methods
We set out to address this question by first analyzing
five microarray datasets accessed through the NCBI
Gene Expression Omnibus (GEO) that measured the
transcriptome of CD133+ versus CD133- CRC cells.
Using patient-derived CRC lines previously established
in our lab, we performed unbiased metabolomics analy-
sis to identify the metabolic signature of CD133+ CCICs
by high-resolution mass spectrometry. Bioinformatics,
metabolic pathway enrichment analysis, and KEGG
pathway online module were then applied to integrate
transcriptomic and metabolomic data.
Results
The transcriptome analysis suggested that CD133+ cells
consistently regulate certain genes differentially from
CD133- cells (3178 genes, p <0.05). Pathway analysis on
the curated gene set highlighted the enrichment of
metabolic pathways, pathways in cancer, and transcrip-
tional misregulation in cancer. Metabolomics studies on
CD133+ and CD133- cells showed differential metabo-
lite levels between the two groups (54 metabolites,
p <0.05). The analysis identified carbohydrate metabolism
(glycolysis, TCA cycle) and cysteine and methionine
metabolism as consistently altered in CCICs, with enzyme
expression matching the corresponding metabolite levels.
Conclusion
Our system-level transcriptomic and metabolomic
analyses on various colorectal cancer sources unraveled
a distinct metabolic signature of CD133+ CCICs
that involve glycolysis, the TCA cycle, and cysteine/
methionine metabolism. The identified metabolic signa-
ture provides insights into reported stem cell-like proper-
ties of CD133+ CCICs. The involved metabolic enzymes
and metabolites may potentially serve as biomarkers for
disease diagnosis and prognosis, and therapeutic targets
for CRC treatment.
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